News Focus
News Focus
Replies to #36551 on Biotech Values
icon url

DewDiligence

10/30/06 2:52 PM

#36554 RE: dewophile #36551

The CEO said the most impressive aspect of the trial vis-à-vis hypoglycemia was that the bedtime oral dose, which was not followed by food, caused no noted hypoglycemia events. The obvious question is how many events were not noted.